White blood cell surface antigen CD47

White blood cell surface antigen CD47
	according to PDB 2JJS
other names	CD47, Antigenic surface determinant protein OA3, Integrin-associated protein, IAP, Leukocyte surface antigen CD47
	Existing structural data : PDB 2JJT , PDB 2VSC
Properties of human protein
Mass / length primary structure	323 amino acids , 35,214 Da
Identifier
External IDs	GeneCards : CD47 ; OMIM : 151460 ; UniProt : Q08722 ;

Leukocyte surface antigen CD47 is a surface protein from the group of cell adhesion molecules .

properties

CD47 binds thrombospondin-1 on platelets . It is glycosylated and phosphorylated .

meaning

The expression of CD47 signals "don't eat me". It protects intact body cells from attack by macrophages . However, it is also expressed by malignant lymphoma and leukemia cells and thus reduces the body's own tumor defense. HU5F9-G4 (formerly 5F9) is an antibody that blocks CD47. In a phase 1 study, HU5F9-G4 in combination with rituximab showed promising activity when used in patients with malignant lymphoma. Further studies must be awaited before clinical application.

Web links

MeSH leukocyte surface antigen CD47

Individual evidence

↑ DR Soto-Pantoja, S. Kaur, DD Roberts: CD47 signaling pathways controlling cellular differentiation and responses to stress. In: Critical Reviews in Biochemistry and Molecular Biology. Volume 50, number 3, 2015, pp. 212-230, doi : 10.3109 / 10409238.2015.1014024 , PMID 25708195 , PMC 4822708 (free full text).
↑ Siddhartha Jaiswal, Catriona HM Jamieson, Wendy W. Pang, Christopher Y. Park, Mark P. Chao: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis . In: Cell . tape 138 , no. 2 , July 23, 2009, ISSN 1097-4172 , p. 271–285 , doi : 10.1016 / j.cell.2009.05.046 , PMID 19632178 , PMC 2775564 (free full text).
↑ Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan: Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential . In: PloS One . tape 10 , no. 9 , 2015, ISSN 1932-6203 , p. e0137345 , doi : 10.1371 / journal.pone.0137345 , PMID 26390038 , PMC 4577081 (free full text).
↑ CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma | NEJM. Accessed February 1, 2019 .

[1] DR Soto-Pantoja, S. Kaur, DD Roberts: CD47 signaling pathways controlling cellular differentiation and responses to stress. In: Critical Reviews in Biochemistry and Molecular Biology. Volume 50, number 3, 2015, pp. 212-230, doi : 10.3109 / 10409238.2015.1014024 , PMID 25708195 , PMC 4822708 (free full text).

[2] Siddhartha Jaiswal, Catriona HM Jamieson, Wendy W. Pang, Christopher Y. Park, Mark P. Chao: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis . In: Cell . tape 138 , no. 2 , July 23, 2009, ISSN 1097-4172 , p. 271–285 , doi : 10.1016 / j.cell.2009.05.046 , PMID 19632178 , PMC 2775564 (free full text).

[3] Jie Liu, Lijuan Wang, Feifei Zhao, Serena Tseng, Cyndhavi Narayanan: Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential . In: PloS One . tape 10 , no. 9 , 2015, ISSN 1932-6203 , p. e0137345 , doi : 10.1371 / journal.pone.0137345 , PMID 26390038 , PMC 4577081 (free full text).

[4] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma | NEJM. Accessed February 1, 2019 .